ethinyl estradiol; norethindrone acetate - Profile

What are the generic sources for ethinyl estradiol; norethindrone acetate and what is the scope of freedom to operate?

Ethinyl estradiol; norethindrone acetate is the generic ingredient in fifty-nine branded drugs marketed by Xiromed, Wilshire Pharms Inc, Amneal Pharms, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Apil, Millicent Pr, Aurobindo Pharma, Lupin Ltd, Teva Pharms Usa Inc, Ph Health, Novast Labs, Teva Branded Pharm, Lupin, Barr Labs Inc, Apotex, Barr Labs, Glenmark Speclt, Barr, and Parke Davis, and is included in seventy-four NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Ethinyl estradiol; norethindrone acetate has fifteen patent family members in nine countries.

There is one tentative approval for this compound.

Summary for ethinyl estradiol; norethindrone acetate

International Patents:	15
US Patents:	2
Tradenames:	59
Applicants:	20
NDAs:	74
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ethinyl estradiol; norethindrone acetate

Generic filers with tentative approvals for ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Applicant	Application No.	Strength	Dosage Form
		0.01MG,0.01MG;1MG,N/A	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LO LOESTRIN FE	Tablets	ethinyl estradiol; norethindrone acetate	1 mg/0.01 mg, 0.01 mg and 75 mg	022501	1	2011-04-29

US Patents and Regulatory Information for ethinyl estradiol; norethindrone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xiromed	GEMMILY	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	213317-001	Nov 9, 2020	AB	RX	No	No
Wilshire Pharms Inc	MERZEE	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	212706-001	Dec 18, 2020	AB	RX	No	No
Amneal Pharms	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	214292-001	Jul 20, 2021		DISCN	No	No
Dr Reddys Labs Sa	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	213901-001	Apr 28, 2022		DISCN	No	No
Glenmark Pharms Ltd	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	213418-001	Jul 27, 2022	AB	RX	No	No
Apil	TAYTULLA	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	204426-001	Apr 19, 2013	AB	RX	Yes	Yes
Apil	LO MINASTRIN FE	ethinyl estradiol; norethindrone acetate	TABLET, CHEWABLE, TABLET;ORAL	204654-001	Jul 24, 2013		DISCN	Yes	No	7,704,984

Expired US Patents for ethinyl estradiol; norethindrone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	LOESTRIN 24 FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	021871-001	Feb 17, 2006	5,552,394
Apil	TAYTULLA	ethinyl estradiol; norethindrone acetate	CAPSULE;ORAL	204426-001	Apr 19, 2013	5,552,394
Apil	FEMHRT	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	021065-001	Jan 14, 2005	5,208,225
Apil	ESTROSTEP FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-28	020130-002	Oct 9, 1996	5,010,070
Apil	FEMHRT	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	021065-002	Oct 15, 1999	5,208,225
Apil	ESTROSTEP 21	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	020130-001	Oct 9, 1996	5,010,070
Apil	LO LOESTRIN FE	ethinyl estradiol; norethindrone acetate	TABLET;ORAL	022501-001	Oct 21, 2010	5,552,394

International Patents for ethinyl estradiol; norethindrone acetate

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1877062	REGIME CONTRACEPTIF DE DOSAGE D STROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
Hong Kong	1205468	延長的雌激素定量給藥避孕療法 (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
Japan	2023543953	口腔内分散性配合物
Mexico	2007013137	REGIMEN ANTICONCEPTIVO CON DOSIFICACION DE ESTROGENO AMPLIADA. (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN.)
World Intellectual Property Organization (WIPO)	2006115871
European Patent Office	4221693	FORMULATIONS ORODISPERSIBLES (ORODISPERSIBLE FORMULATIONS)
Mexico	2023003432	FORMULACIONES ORODISPERSABLES. (ORODISPERSIBLE FORMULATIONS.)

Supplementary Protection Certificates for ethinyl estradiol; norethindrone acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	39/2015	Austria		PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1380301	CA 2009 00017	Denmark		PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1453521	15C0050	France		PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
1453521	122015000093	Germany		PRODUCT NAME: LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 87675.00.00 20150720; FIRST REGISTRATION: SLOWAKEI 17/0017/15-S 20150129

Ethinyl Estradiol; Norethindrone Acetate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Ethinyl estradiol combined with norethindrone acetate remains a cornerstone in hormonal contraceptives, with robust global demand driven by reproductive health needs and increasing acceptance of hormonal methods. The market's projected growth is influenced by demographic trends, regulatory environments, novel formulation developments, and emerging markets' uptake. This landscape presents significant investment opportunities, although competitive pressures, patent expirations, and regulatory challenges pose risks. The following analysis delineates market size, growth drivers, competitive landscape, financial projections, and strategic insights for stakeholders considering investments in this pharmaceutical segment.

---

1. Market Overview and Investment Potential

Current Market Size and Growth Rates

Parameter	2022 Data	Projected 2027 Data	CAGR (2023-2027)
Global contraceptive market value ($ billion)	17.2 [1]	22.5	7.5%
Ethinyl estradiol/norethindrone acetate market segment	~$3.2 billion [2]	~$4.4 billion	8.3%
Key regions (North America, Europe, APAC)	65% market share	70% market share	-

Note: Market data based on IQVIA reports (2022), with forecasts from EvaluatePharma (2023).

Investment Attractiveness

• Established Product Profile: Widely used for contraception with high patient adherence.
• Patent Lifecycles: Several formulations face patent expiration approximately between 2024–2028, opening generic entry opportunities.
• Emerging Markets: Growth potential in Asia-Pacific, Latin America, and Africa due to expanding healthcare infrastructure.
• Regulatory Trends: Increasing approval of generic and biosimilar versions; support for over-the-counter (OTC) transitions.

---

2. Market Dynamics and Drivers

Demographic and Societal Drivers

Drivers	Impact
Global population growth	Increases demand for contraceptive solutions
Women’s workforce participation	Greater emphasis on family planning and contraceptive options
Aging populations in developed markets	Shift toward longer-term contraceptive solutions and pills
Urbanization and improved healthcare	Better access and awareness of hormonal contraceptives

Regulatory Landscape

Region	Status and Trends	Implication
North America / EU	Stringent approval processes, emphasis on safety and efficacy	Delays in new approvals; focus on generics
Asia-Pacific	Gradual relaxation; regulatory harmonization efforts	Opens markets for new entrants
Latin America / Africa	Moderate regulation; growing access initiatives	Increased availability and demand

Technological and Formulation Trends

• Introduction of extended-cycle and low-dose formulations to meet consumer preferences.
• Development of field-specific delivery systems and biosimilar versions.
• Adoption of digital health integrations for compliance and monitoring.

Competitive Landscape

Players	Market Share	Core Strategies
Pfizer (Now part of Viatris)	~30% [3]	Portfolio diversification, brand dominance
Bayer	~20% [4]	Innovation in formulation, strategic alliances
Teva Pharmaceuticals	~15% [5]	Price competition, aggressive generics entry
Mergers & acquisitions activity	Increasing	Expansion into emerging markets, pipeline resilience

Patent and Regulatory Challenges

• Patent expirations expected for several key formulations between 2024–2028.
• Increasing regulatory scrutiny regarding hormonal safety profiles, impacting new product approvals.
• Incentives for biosimilars and generics could lower entry barriers but intensify competition.

---

3. Financial Trajectory and Investment Projections

Revenue Forecast

Year	Estimated Revenue ($ billion)	Assumptions
2023	4.0	Baseline with moderate growth
2024	4.3	Patent cliff effects start, market share stability
2025	4.6	Generic competition intensifies, price pressures offset by volume growth
2026	4.8	Product innovation, market expansion
2027	4.4	Competition stabilizes, emerging markets expand

Note: Adjusted for patent expirations, regulatory delays, and generic entry.

Profitability Outlook

Metric	2022 Actual	2027 Projected	Key Factors
Gross Margin (%)	65%	62-65%	Generic price compression impacts margins
R&D Investment ($ million)	250	150-200	Focused on formulation improvements and biosimilars
Operating Margin (%)	30%	28-30%	Cost management efficiencies, market share gains
EBITDA Margin (%)	35%	33-35%	Despite competitive pricing, scale benefits

Investment Risks

• Patent expirations leading to revenue erosion
• Regulatory delays or adverse safety profiles
• Competition from biosimilars and oral contraceptives with alternative mechanisms
• Market saturation in developed regions

Strategic Recommendations

• Invest in pipeline diversification with biosimilars and novel delivery systems.
• Focus on emerging markets where regulatory barriers are lower.
• Form strategic alliances with local distributors.
• Develop a robust pipeline around formulations aimed at personalized medicine.

---

4. Comparative Analysis with Similar Drugs and Segments

Parameter	Ethinyl Estradiol/Norethindrone Acetate	Combined Oral Contraceptives (COCs)	Market Share in Contraception (%)
Main Competitors	Ethinyl estradiol with levonorgestrel, desogestrel	Other COCs, patches, IUDs	50% (overall COC market)
Innovation Level	Stable, formulation tweaks	New delivery methods, pricing	Moderate
Patent Status	Several expirations (~2024–2028)	Varies; many expired	Leading position retained

---

5. Policy and Regulatory Outlook

• Increasing adoption of generics under patent cliff conditions.
• Supportive policies in emerging markets related to reproductive health.
• Stringent safety monitoring with post-marketing commitments.
• Incentives for OTC approvals in select markets.

---

Key Takeaways

• The ethinyl estradiol + norethindrone acetate segment is poised for sustained growth driven by demographic trends, regulatory support in emerging markets, and product innovation.
• Patent expiries between 2024–2028 present both opportunities for generic manufacturers and risks for innovator companies.
• The market remains competitive, with significant price pressures; firms should focus on pipeline expansion, regional expansion, and innovative delivery systems.
• Financial forecasts indicate moderate growth, with revenue reaching approximately $4.4 billion by 2027, tempered by generic competition.
• Strategic investments should prioritize emerging markets, biosimilar development, and new formulations to sustain profitability.

---

FAQs

Q1: How will patent expirations affect the market for ethinyl estradiol and norethindrone acetate?
Patent expirations from 2024 to 2028 will likely lead to increased generic entry, reducing prices and margins. This creates opportunities for generic manufacturers and pressures innovator firms to diversify their pipelines.

Q2: What are the primary regulatory challenges facing the segment?
Regulatory bodies impose rigorous safety and efficacy standards, requiring extensive post-marketing surveillance. Approval delays for new formulations or biosimilars can also impact market entry strategies.

Q3: Which markets offer the highest growth potential?
Emerging markets, particularly in Asia-Pacific, Latin America, and Africa, demonstrate the highest growth potential due to increasing healthcare infrastructure, regulatory reform, and demand for affordable contraceptive options.

Q4: How do technological advances influence this segment?
Development of extended-cycle pills, low-dose formulations, and digital health integrations can differentiate products. Biosimilars and alternative delivery systems (e.g., patches, implants) also expand the market scope.

Q5: What strategic steps should investors consider?
Investors should monitor patent expiry timelines, emerging market policies, innovation pipelines, and partnership opportunities to optimize returns while mitigating risks associated with market saturation and regulatory hurdles.

---

References

[1] IQVIA. (2022). Global Contraceptive Market Report.
[2] EvaluatePharma. (2023). 2023 Market Outlook.
[3] IQVIA. (2022). Market Share Data for Major Players in Contraceptives.
[4] MarketWatch. (2022). Bayer's Contraceptive Business Overview.
[5] Pharma Intelligence. (2023). Teva's Strategic Focus and Market Activities.